Naito et al. [16] showed that the proportion of pathological stage II, III and IV NSCLC was higher with SWI/SNF loss and that SWI/SNF loss was associated with shorter OS and recurrence-free survival than SWI/SNF intact in stage I NSCLC. The gene discussed is SMARCA1; the disease is non-small cell lung carcinoma.